SOUTH
PLAINFIELD, N.J., July 17,
2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:
PTCT) today announced the appointment of Pierre Gravier to the role of Chief Financial
Officer (CFO). Mr. Gravier brings more than 17 years of experience
as an investment banker, venture capitalist and scientist to PTC.
Most recently, Pierre was a managing director in the healthcare
group of Perella Weinberg Partners, a leading independent global
advisory firm. At Perella Weinberg, he focused on advising
companies in the biopharmaceutical and pharmaceutical sectors on
finance strategy and corporate development.
"We are incredibly excited to have Pierre as part of PTC's
leadership team," said Matthew B.
Klein, M.D., Chief Executive Officer, PTC Therapeutics.
"Pierre's extensive global experience in finance and healthcare
advisory will be incredibly helpful as we continue to build the PTC
of tomorrow. Having known Pierre over the past several years, I am
confident his knowledge, experience and passion to help patients
make him a great addition to the PTC family."
Prior to joining Perella Weinberg, Pierre worked as a healthcare
investment banker at Barclays Capital in London. Previously, he was a venture capital
analyst at Société Générale Asset Management in Paris, where he focused on early-stage
investments in the biotechnology sector. Mr. Gravier began his
career as a scientist at Ferring Pharmaceuticals. Pierre holds a
master's degree in finance from ESCP Business School and a Master
of Science in bioengineering from the University of Technology of
Compiègne.
"I am excited to join the patient-focused and mission-driven PTC
team and look forward to supporting our continued efforts to
deliver transformational therapies to patients with high unmet
medical need," said Pierre
Gravier.
About PTC Therapeutics, Inc.
PTC is a global
biopharmaceutical company focused on the discovery, development and
commercialization of clinically differentiated medicines that
provide benefits to patients with rare disorders. PTC's ability to
innovate to identify new therapies and to globally commercialize
products is the foundation that drives investment in a robust and
diversified pipeline of transformative medicines. PTC's mission is
to provide access to best-in-class treatments for patients who have
little to no treatment options. PTC's strategy is to leverage its
strong scientific and clinical expertise and global commercial
infrastructure to bring therapies to patients. PTC believes this
allows it to maximize value for all its stakeholders. To learn more
about PTC, please visit us at www.ptcbio.com and follow us on
Facebook, Instagram, LinkedIn and Twitter at @PTCBio.
For More Information:
Investors:
Kylie
O'Keefe
+1 (908) 300-0691
kokeefe@ptcbio.com
Media:
Jeanine
Clemente
+1 (908) 912-9406
jclemente@ptcbio.com
Forward-Looking Statements:
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. All statements contained in this release, other than
statements of historic fact, are forward-looking statements,
including statements regarding PTC's strategy, future operations,
future financial position, future revenues, projected costs; and
the objectives of management. Other forward-looking statements may
be identified by the words "guidance," "plan," "anticipate,"
"believe," "estimate," "expect," "intend," "may," "target,"
"potential," "will," "would," "could," "should," "continue," and
similar expressions.
PTC's actual results, performance or achievements could differ
materially from those expressed or implied by forward-looking
statements it makes as a result of a variety of risks and
uncertainties, including the factors discussed in the "Risk
Factors" section of PTC's most recent Annual Report on Form 10-K as
well as any updates to these risk factors filed from time to time
in PTC's other filings with the SEC. You are urged to carefully
consider all such factors.
The forward-looking statements contained herein represent PTC's
views only as of the date of this press release and PTC does not
undertake or plan to update or revise any such forward-looking
statements to reflect actual results or changes in plans,
prospects, assumptions, estimates or projections, or other
circumstances occurring after the date of this press release except
as required by law.
View original
content:https://www.prnewswire.com/news-releases/ptc-therapeutics-appoints-experienced-healthcare-finance-strategist-pierre-gravier-as-chief-financial-officer-301878977.html
SOURCE PTC Therapeutics, Inc.